Travere Therapeutics Inc. (TVTX) is now just one step away from potential FDA approval of FILSPARI for expanded use in treating focal segmental glomerulosclerosis (FSGS), following notification that an advisory committee review will no longer be required. Shares are up over 16% at $25 in premarket hours today.
Focal Segmental Glomerulosclerosis or FSGS is a leading cause of kidney failure and currently has no approved pharmacological treatments.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.